Maropitant: what the FDA reviewed for dog products
5 Freedom of Information summaries from the FDA Center for Veterinary Medicine for products containing Maropitant, as typed records: every value below is followed by the verbatim passage it was taken from. Species as stated by each summary: Cats; Dogs; Dogs and cats.
Products
- Cerenia® Injectable Solution (NADA/ANADA 141-263)
- Cerenia® Tablets (NADA/ANADA 141-262)
- Maropitant Citrate (NADA/ANADA 200-710)
Maropitant Citrate NADA 200-710, Original approval, December 05, 2025; sponsor Dechra Veterinary Products LLC; species: Dogs and cats; foi_id 17776; FDA PDF
Indication
Dogs: prevention and treatment of acute vomiting. Cats: treatment of vomiting. (Generic of Cerenia injectable, NADA 141-263.)
Dose regimen
1 mg/kg (0.45 mg/lb), i.e. 0.1 mL/1 kg (1 mL/22 lb), intravenous over 1-2 minutes or subcutaneous (dogs 2-4 months: subcutaneous only), once daily, for up to 5 consecutive days; single dose 45-60 minutes before emetogenic/chemotherapeutic agents; cats 4 months and older same dose IV or SC
Dogs 4 months of Age and Older: Administer Maropitant Citrate Injectable Solution intravenously over 1-2 minutes or subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 0.1 mL/1 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.
Extraction notes: Generic (ANADA) approval granted a biowaiver: the injectable solution has the same active ingredient, concentration and dosage form as the RLNAD with no inactive ingredients affecting bioavailability, so no in vivo bioequivalence, effectiveness, PK or safety studies are summarised. Minimal record (indication and dose regimen only).
Cerenia® Tablets NADA 141-262, Original approval, January 29, 2007; sponsor Zoetis Inc.; species: Dogs; foi_id 816; FDA PDF
Indication
Prevention of acute vomiting in dogs; prevention of vomiting due to motion sickness in dogs.
Dose regimen
acute vomiting: minimum 2.0 mg/kg; motion sickness: minimum 8.0 mg/kg, oral (tablet), once daily, acute vomiting: up to 5 consecutive days; motion sickness: up to 2 consecutive days
Prevention of acute vomiting: administer a minimum of 2.0 mg/kg body weight once daily for up to 5 consecutive days. Prevention of vomiting due to motion sickness: administer a minimum of 8.0 mg/kg body weight once daily for up to 2 consecutive days.
Pharmacokinetics
| Parameter | Value | Conditions | Quote |
|---|---|---|---|
| other | greater-than-dose-proportional increase in systemic exposure (dose-normalized Cmax and AUC0-30) from 6 to 8 mg/kg | oral non-final tablets, fasted Beagles, two-period crossover, 8 dogs per sequence (study 1566E-60-02-642); Cmax, AUC0-30 and T1/2 at 8 mg/kg significantly larger than at 6 mg/kg (P < 0.05) | Dose-normalized Cmax and AUC0-30 demonstrated that increasing the administered dose from 6 to 8 mg/kg provided a greater-than-dose-proportional increase in systemic drug exposure. |
Target-animal safety
dose multiples 1X, 3X, 5X; duration once daily for 15 days at 0, 2, 6 and 10 mg/kg (2 mg/kg acute-vomiting dose) in Beagles at least 16 weeks old; recovery group to Day 43; animals 28 male and 28 female.
Twenty-eight male and 28 female Beagle dogs were used in this study (minimum 16 weeks of age on Day 0).
| Finding | Quote |
|---|---|
| Food consumption ~13% (2 mg/kg) and ~11% (10 mg/kg) lower than placebo; body weight ~2% lower at 2, 6 and 10 mg/kg; effects did not persist after dosing. | Food consumption in dogs receiving maropitant at 2 mg/kg/day and 10 mg/kg/day was lower (approximately 13% and 11%, respectively) than placebo. Body weights in dogs treated with maropitant at 2, 6 and 10 mg/kg/day were slightly lower (approximately 2%) than placebo. |
| Conclusion of the 2 mg/kg margin-of-safety study. | Maropitant caused decreases in food consumption and body weight that were not dose-dependent and did not persist after cessation of treatment. This study supports the safe use of maropitant citrate at 2 mg/kg/day for 5 days in 16 week old dogs. |
| 8 mg/kg study (0, 8, 24 mg/kg for 6 days, 40 dogs 16-18 weeks): decreased body weight at 8 mg/kg; at 24 mg/kg decreased food consumption, body weight, liver and testis weight, lethargy, decreased phosphorus, increased RBC. | Maropitant administered at 8 mg/kg orally for 6 days to 16 week old Beagle dogs caused decreased body weight. Maropitant administered at 24 mg/kg orally for 6 days to 16 week old Beagle dogs (8 males and 8 females) caused decreased food consumption, body weight, liver and testis weight, lethargy, decreased phosphorus, and increased RBC count. |
| Studies in 8-week-old puppies showed bone marrow hypoplasia (and lymphoid depletion, one death at 24 mg/kg) and did not support use in puppies 8-11 weeks of age. | In this study with 8 week old puppies, one dog treated with 24 mg/kg/day of maropitant died suddenly on treatment day 2 and no definitive cause of death was determined. Additionally, increased frequency and severity of bone marrow hypoplasia and lymphoid depletion of spleen, thymus, and lymph nodes was reported for dogs treated with elevated doses of maropitant (Table 4.1). |
| Tolerance study (7 days): 20-30 mg/kg caused occasional vomiting; 40-50 mg/kg caused weight loss, vomiting, soft stools, weakness, lethargy, salivation, hypokalemia, neutropenia. | Maropitant tablets, administered at 40 and 50 mg/kg orally once a day for 7 days caused clinically relevant signs of weight loss, vomiting, soft stools, weakness, lethargy, salivation, and hypokalemia. Additionally, leukopenia characterized as a neutropenia, and a trend toward decreasing plasma phosphorus values were seen. |
Effectiveness
Field safety and effectiveness study 1467C-60-01-597 (6 US sites): placebo-controlled study in client-owned dogs presented for acute vomiting; maropitant 1 mg/kg SC on Day 0 then oral minimum 2 mg/kg or SC once daily as needed for up to 5 days; 275 enrolled (206 maropitant, 69 placebo), 199 in effectiveness analysis.; n = 199; primary endpoint: Evidence of vomiting during the study period; result: 27/54 placebo dogs (50%) vs 31/145 maropitant dogs (21.4%) vomited at some time during the study. Motion-sickness field studies: vomiting during journey in 8/122 (6.6%) maropitant vs 67/122 (55%) placebo (dosed 2 h before travel, P < 0.0001) and 3/22 (13.6%) vs 16/22 (72.7%) (dosed 10 h before travel, P = 0.03).
Of the 199 dogs included in the statistical summary of effectiveness, 27 of 54 dogs (50%) in the placebo group displayed vomiting at some time during the study and 31 of 145 dogs (21.4%) in the maropitant- treated group displayed vomiting during the study period.
Adverse reactions
| Term | Treated | Control | Quote |
|---|---|---|---|
| Death during study (acute vomiting field study; placebo n=69, maropitant n=206) | 10 (4.9%) | 4 (5.8%) | Death during study 4 5.8 10 4.9 |
| Diarrhea (acute vomiting field study) | 8 (3.9%) | 6 (8.7%) | Diarrhea 6 8.7 8 3.9 |
| Hematochezia/bloody stool (acute vomiting field study) | 4 (1.9%) | 5 (7.2%) | Hematochezia/bloody stool 5 7.2 4 1.9 |
| Anorexia (acute vomiting field study) | 3 (1.5%) | 2 (2.9%) | Anorexia 2 2.9 3 1.5 |
| Salivation (motion sickness field study, 8 mg/kg 2 h before travel; maropitant n=148, placebo n=150) | 10 (6.8%) | 8 (5.3%) | Salivation 10 6.8 8 5.3 |
| Vomiting (European motion sickness field safety study; placebo n=106, maropitant n=107) | 10 (9%) | 4 (4%) | Vomiting 4 4 10 9 |
Extraction notes: Very large summary. PK numeric values are not tabulated in this summary (only the qualitative 6 vs 8 mg/kg comparison); numeric repeat-dose PK appears in the 2015 supplement (foi 817). TAS design_quote is the 15-day 0/2/6/10 mg/kg study (1X/3X/5X of the 2 mg/kg dose); the 8 mg/kg motion-sickness dose was tested at 8 and 24 mg/kg (1X/3X) for 6 days. Adverse reaction quotes are flattened table rows: Tables 3.5 and 5.1 have columns placebo # dogs, placebo %, maropitant # dogs, maropitant %; Table 4.3 has maropitant first then placebo. Two lab cisplatin/apomorphine dose-confirmation studies are not reproduced.
Cerenia® Tablets NADA 141-262, Supplemental approval, June 17, 2015; sponsor Zoetis Inc.; species: Dogs; foi_id 817; FDA PDF
Indication
Prevention of acute vomiting and prevention of vomiting due to motion sickness in dogs; supplement extends consecutive use for acute vomiting in dogs 7 months and older from 5 days to until resolution of acute vomiting.
Dose regimen
minimum 2 mg/kg (0.9 mg/lb) for acute vomiting, oral (tablet), once daily, dogs 7 months and older: until resolution of acute vomiting; dogs 2-7 months: up to 5 consecutive days; motion sickness (4 months and older): minimum 8 mg/kg (3.6 mg/lb) once daily for up to 2 consecutive days
Prevention of Acute Vomiting in dogs 7 months and older: Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily until resolution of acute vomiting.
Pharmacokinetics
| Parameter | Value | Conditions | Quote |
|---|---|---|---|
| cmax | 154 (SD 111) ng/mL; 304 (165) ng/mL; 588 (416) ng/mL; 1409 (516) ng/mL | table columns in order: low dose single, low dose after repeat daily dosing, high dose single, high dose after repeat daily dosing (low dose = 2 mg/kg, high dose = 8 mg/kg, 14 consecutive days); CERENIA tablets after overnight fast, 8 Beagles per dose (4M/4F); maropitant (CJ-11972); mean (SD) | Cmax (ng/mL) 154 (111) 304 (165) 588 (416) 1409 (516) |
| auc | AUC(0-24) 1440 (982) ng*hr/mL; 3890 (3030); 6730 (5030); 26600 (9200) ng*hr/mL | same column order (low dose single, low dose repeat, high dose single, high dose repeat); same 14-day repeat-dose study, mean (SD) | AUC(0-24) (ng*hr/mL) 1440 (982) 3890 (3030) 6730 (5030) 26600 (9200) |
| tmax | 2.0 h (1.5-3.0); 1.5 h (1.0-3.0); 1.5 h (1.0-3.0); 2.5 h (1.5-7.0) | median (range); same column order (low dose single, low dose repeat, high dose single, high dose repeat) | Tmax b (hr) 2.0 (1.5 – 3.0) 1.5 (1.0 – 3.0) 1.5 (1.0 – 3.0) 2.5 (1.5 – 7.0) |
| half-life | 9.22 (5.79, 12.6) hr after 14th daily 2 mg/kg dose; 21.7 (3.6, 29.7) hr after 14th daily 8 mg/kg dose | mean T1/2 after last dose, non-linear kinetics attributed to saturable metabolism | The mean T1/2 after the 14th dose was 9.22 (5.79, 12.6) hr for 2 mg/kg and 21.7 (3.6, 29.7) hr for 8 mg/kg. |
| other | accumulation ratio in AUC(0-24) 4.81 (95% CI 3.28, 7.05) at 8 mg/kg and 2.46 (1.68, 3.61) at 2 mg/kg | 14 daily doses vs single dose | CJ-11972 accumulation was substantially greater after fourteen 8 mg/kg doses than after fourteen 2 mg/kg doses as reflected in an accumulation ratio in AUC(0-24) of 4.81 (95% CI: 3.28, 7.05) at 8 mg/kg and 2.46 (1.68, 3.61) at 2 mg/kg |
| other | steady state reached after the 4th dose (CJ-11972) and 3rd dose (metabolite CJ-18518) | sequential tests on trough concentrations | Steady state determination based on sequential tests for Ct (trough) indicated that the steady state was reached after the 4th dose for CJ-11972 and the 3rd dose for CJ-18518. |
Target-animal safety
dose multiples 1 mg/kg/day, 5 mg/kg/day, 20 mg/kg/day; duration once daily by oral gavage for 93 days (3-month oral toxicity study) in 7-month-old Beagles; animals 6 (3M, 3F) per group, 4 groups.
1 0 mg/kg Oral 6 (3M, 3F) 2 1 mg/kg/day Oral 6 (3M, 3F) 3 5 mg/kg/day Oral 6 (3M, 3F) 4 20 mg/kg/day Oral 6 (3M, 3F)
| Finding | Quote |
|---|---|
| Salivation, emesis and loose stools more prevalent at 20 mg/kg/day. | Sporadic occurrences of salivation were observed among both control dogs and dogs administered maropitant, but were generally more prevalent at 20 mg/kg/day. |
| All 6 dogs at 20 mg/kg/day lost body weight (1.3-15.2%); 1/6 at 5 mg/kg/day lost 7.3%; 3/6 at 1 mg/kg/day lost 1.2-4.5%. | Six (6/6) dogs administered maropitant at 20 mg/kg/day had a decrease in body weight (1.3-15.2%). One dog (1/6) administered maropitant at 5 mg/kg/day had a 7.3% decrease in body weight. Three (3/6) dogs administered maropitant at 1 mg/kg/day had a decrease in body weight (1.2-4.5%). |
| EKG changes limited to 20 mg/kg/day: trends toward increased P-R interval, P wave duration and QRS amplitude. | Changes in EKG parameters were limited to dogs administered maropitant at 20 mg/kg/day. These consisted of trends toward increased P-R interval, P wave duration, and QRS amplitude over the course of drug treatment. |
| Lower serum albumin at 20 mg/kg/day; one 20 mg/kg/day female with lower red cell parameters, higher reticulocytes/platelets and increased bone marrow cellularity; adrenal vacuolation at 5 and 20 mg/kg/day. | Increased cellularity of the bone marrow was observed in one female dog administered maropitant at 20 mg/kg/day. This female dog had also lower red cell parameters with corresponding higher percent reticulocytes. Higher group mean absolute and relative adrenal weights were apparent at 20 mg/kg/day in females. |
| Conclusion: supports safe use at 2 mg/kg/day in dogs 7 months and older for prevention of acute vomiting. | This study supports the safe use of maropitant citrate administered at 2 mg/kg/day in dogs 7 months of age and older for prevention of acute vomiting. |
Extraction notes: Supplemental approval extending duration of use; no effectiveness studies required. TAS is a 3-month oral gavage toxicity study (24 Beagles, 6 per group at 0, 1, 5, 20 mg/kg/day; the summary does not express these as label-dose multiples, so dose_multiples lists the doses; design_quote is the flattened treatment-group table with columns group, dose, route, number and gender). PK quotes are flattened rows of Table 1 (columns: 2 mg/kg single, 2 mg/kg repeat, 8 mg/kg single, 8 mg/kg repeat; values are mean (SD) except Tmax median (range)). No adverse reaction table in this summary.
Cerenia® Injectable Solution NADA 141-263, Supplemental approval, May 16, 2012; sponsor Zoetis Inc.; species: Cats; foi_id 819; FDA PDF
Indication
Supplement adds the indication for the treatment of vomiting in cats (product also indicated for prevention and treatment of acute vomiting in dogs).
Dose regimen
1 mg/kg (0.45 mg/lb), i.e. 1 mL/10 kg (1 mL/22 lb), subcutaneous injection, once daily, for up to 5 consecutive days
Administer CERENIA Injectable Solution subcutaneously at 1 mg/kg (0.45 mg/lb) equal to 1 mL/10 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.
Pharmacokinetics
| Parameter | Value | Conditions | Quote |
|---|---|---|---|
| other | exposure dose-proportional between 1 mg/kg and 3 mg/kg SC; slightly greater than dose-proportional at 5 mg/kg daily | 16-week-old cats, subcutaneous once daily for 15 days (margin of safety study); parent CERENIA and metabolite CJ-18,518; numeric AUC/Cmax shown only as a figure | Drug concentrations were found to be proportional following a subcutaneous injection of 1 mg/kg or 3 mg/kg, and concentrations of the parent compound and its active metabolite were slightly greater than dose proportional after a daily subcutaneous injection of 5 mg/kg. |
Target-animal safety
dose multiples 1X, 3X, 5X; duration subcutaneous once daily for 15 days at 0, 1, 3 and 5 mg/kg in cats approximately 16 weeks of age (GLP); animals 16 male and 16 female (8 per group).
Sixteen male and 16 female cats were randomly assigned to 1 of 4 Groups consisting of 8 cats each, and received treatment as described in Table 7.
| Finding | Quote |
|---|---|
| Dose-dependent pain on subcutaneous injection: moderate + marked behavioral responses in 5.8% (control), 36.7% (1X), 70.8% (3X) and 72.5% (5X) of injections. | Moderate + Marked 7 5.8 44 36.7 85 70.8 87 72.5 |
| Additional restraint needed dose-dependently; other signs included persistent attention to injection site, salivation, growling, urination, aggressive posturing and vomiting. | Other observations related to administration of CERENIA included persistent attention to the injection site (licking, scratching, attempted biting), conditioned behavioral responses (salivation, growling), urination, licking of the injection site, aggressive posturing, and vomiting. |
| Dose-dependent injection site pain, heat, redness and firmness (firmness ≤10 mm: 2, 39, 96, 128 observations in Groups 1-4). | There was a dose dependent increase in injection site pain, heat, and redness in the multiple injection sites, associated with the administration of CERENIA. |
| Body weight unaffected; Group 4 (5X) calorie consumption slightly lower (p = 0.0171); one 3X cat with elevated APTT 76.2 s on Day 14. | Body weight was not affected by treatment. Average daily calorie consumption in Group 4 was slightly (~ 7 g/day) lower but statistically significantly different (p = 0.0171) compared to Group 1. |
| Injection-site histopathology: early dose-dependent acute inflammation replaced by fibrosis and decreasing granulomatous inflammation; no treatment-related gross findings. | Overall, histopathologic evaluation of the injection sites showed there was a n early dose dependent acute inflammatory response (neutrophilic and mixed cell inflammation, collagen degeneration, and edema) that was replaced by increased fibrosis and decreasing granulomatous inflammation. |
| Conclusion. | The subcutaneous administration of CERENIA at 1, 3, and 5 mg/kg in 16- week-old cats results in injection pain and results in the need for increased restraint during injections. CERENIA also causes injection site reactions (pain, heat, redness, firmness) and inflammatory histological changes at the injection site. |
Effectiveness
Field effectiveness study 1982C-60-09-347 (22 US sites): masked, randomized (2:1), placebo (saline)-controlled study in cats presented with vomiting; CERENIA 1.0 mg/kg SC once daily for up to 5 days; 195 cats enrolled (133 CERENIA, 62 placebo), 165 in per-protocol effectiveness set (111 CERENIA, 54 placebo).; primary endpoint: Treatment success = absence of vomiting from first treatment to the 24-hour assessment; result: Treatment success 98.2% with CERENIA vs 81.5% with placebo (p = 0.0102); 2 CERENIA-treated vs 10 placebo cats vomited in the first 24 hours.
The difference in proportion of treatment success between treatment groups was statistically significant (p = 0.0102). The percentage of animals successfully treated for vomiting with placebo was 81.5% and CERENIA was 98.2%.
Adverse reactions
| Term | Treated | Control | Quote |
|---|---|---|---|
| Moderate response to injection (field study; placebo n=62, CERENIA n=133) | 30 (22.6%) | 1 (1.6%) | Moderate Response to Injection1,2 1 1.6 30 22.6 |
| Significant response to injection (field study) | 15 (11.3%) | 1 (1.6%) | Significant Response to Injection1,3 1 1.6 15 11.3 |
| Fever/Pyrexia (field study) | 2 (1.5%) | 2 (3.2%) | Fever/Pyrexia 2 3.2 2 1.5 |
| Dehydration (field study) | 3 (2.3%) | 0 (0.0%) | Dehydration 0 0.0 3 2.3 |
| Lethargy (field study) | 2 (1.5%) | 0 (0.0%) | Lethargy 0 0.0 2 1.5 |
| Anorexia (field study) | 1 (0.8%) | 0 (0.0%) | Anorexia 0 0.0 1 0.8 |
Extraction notes: This supplemental summary is for CATS (species_class 'Cats') although filed under a dog application; n_dogs is left null (165 evaluable cats / 195 enrolled). The general information/effectiveness/TAS sections were not parsed, so quotes come from the raw text. Adverse reaction quotes are flattened Table 6 rows (columns: placebo # cats, placebo %, CERENIA # cats, CERENIA %; 'Injection1,2' carries footnote superscripts). TAS behavioural-response quote is a flattened Table 10 row (columns: Group 1-4 number and % of 120 injections). Dose selection (40 cats, xylazine model) and dose confirmation (36 cats) studies are not reproduced.
Cerenia® Injectable Solution NADA 141-263, Supplemental approval, May 16, 2012; sponsor Zoetis Inc.; species: Dogs; foi_id 820; FDA PDF
Indication
Prevention and treatment of acute vomiting in dogs; supplement decreases the minimum age to dogs 8 weeks and older.
Dose regimen
1 mg/kg (0.45 mg/lb), i.e. 1 mL/10 kg (1 mL/22 lb), subcutaneous injection, once daily, for up to 5 consecutive days
Administer CERENIA Injectable Solution subcutaneously (SC) at 1 mg/kg (0.45 mg/lb) equal to 1 mL/10 kg (1 mL/22 lb) of body weight once daily for up to 5 consecutive days.
Pharmacokinetics
| Parameter | Value | Conditions | Quote |
|---|---|---|---|
| other | lower than expected exposure after 1 mg/kg SC or 2 mg/kg oral in 10 week old dogs | 10-week-old Beagles, study 1467R-60-08-853, compared with prior data in 16-week-old dogs; exposure after the 8 mg/kg oral dose was comparable to adult Beagles | 10 week old dogs in this study that received either a 1 mg/kg CERENIA Injectable or 2 mg/kg CERENIA Tablet dose showed lower than expected drug exposure. |
Target-animal safety
dose multiples 1X; duration label doses in 10-week-old Beagles: 8 mg/kg oral on days 0-1 (motion sickness dose); 1 mg/kg SC or 2 mg/kg oral on days 0-4 (acute vomiting doses); non-GLP; animals 20 male and 20 female.
Twenty male and 20 female Beagle dogs were used in this study.
| Finding | Quote |
|---|---|
| Main finding: decreased food consumption in males at 8 mg/kg oral for 2 days; mild flinching/shaking at injection; transient diarrhea in all groups including controls. | The main treatment related finding in the study was a decrease in food consumption in males that received maropitant at 8 mg/kg for 2 days compared to control dogs. Flinching and shaking/scratching were more frequent and persistent in maropitant injected dogs compared to the corresponding control dogs. |
| Two dogs at 8 mg/kg oral had reticulocyte counts below reference range; fibrinogen increased in 8 mg/kg oral and 1 mg/kg SC groups. | In T02 (8 mg/kg oral CERENIA Tablet), 2 dogs had individual values below the reference range for reticulocyte counts. Unlike other dogs in T02, these 2 dogs did not have elevated hematocrit and hemoglobin values. |
| One male at 1 mg/kg SC had minimal hypocellular femoral bone marrow; clinical significance undetermined. | One male dog in T04 (1 mg/kg CERENIA Injectable) had hypocellular femoral bone marrow. The pathologist described the finding as minimal (scored 1 of possible 4). |
| Conclusion: well tolerated in 10-week-old puppies; minimum age for acute vomiting lowered to 8 weeks, motion sickness remains 16 weeks because of the higher dose. | Maropitant was well tolerated in healthy puppies 10 weeks of age. The main treatment related findings were mild pain associated with injection and a decrease in food consumption in males orally administered maropitant at 8 mg/kg for 2 days. Hypocellular bone marrow was observed in 1 dog administered 1 mg/kg CERENIA Injectable; the clinical significance of this finding remains undetermined. |
Extraction notes: Supplemental approval lowering the minimum age; no effectiveness studies required. Single TAS study at label doses only (five groups of 8: placebo tablet, 8 mg/kg tablet, saline SC, 1 mg/kg SC, 2 mg/kg tablet), so dose_multiples is ['1X']. No summary statistics were analysed (summary statistics only) and no adverse reaction table exists. Original 8-week-old studies (NADA 141-263, 2007) showed dose-related bone marrow hypocellularity at 24 mg/kg.
Reproduce: foi_structured_search(query="Maropitant") and foi_summary_get(foi_id=...) in dog-geroscience-mcp; dataset foi-summaries-dog (config structured).